

February 25, 2026
D SOLVE Academy: Empowering Exchange, Elevating Hepatitis D Care
The D‑SOLVE Academy is the training and exchange hub of the D‑SOLVE project. It connects clinicians, researchers, and early‑career scientists across Europe with the shared goal of accelerating progress in diagnostics, monitoring, and care for hepatitis D (HDV). By coordinating structured exchanges between D‑SOLVE partners, delivering targeted education, and building international links, the Academy ensures that scientific advances translate efficiently into clinical practice. The Academy is also open for scientists and physicians from other institutes and clinical hospitals (“train the trainer”), extending its impact beyond the consortium.
At its core, the Academy enables practical, hands‑on learning through bilateral site visits and short‑term exchanges among D‑SOLVE partner institutions. These visits foster direct knowledge transfer in HDV diagnostics and patient management, help align clinical workflows and methodologies, and strengthen collaboration between clinical and research teams.
Training is anchored by the D‑SOLVE Translational Seminar Series, which bridges basic science and clinical practice in viral hepatitis – with a focus on HBV/HDV – through curated sessions for experts and young investigators; a detailed summary is available in a separate news post on this website.
Beyond Europe, the Academy has also initiated targeted international collaboration, including an emerging partnership with Nigerian researcher Dr. Ijeoma Ifeorah (Department of Medical Laboratory Sciences, College of Medicine, University of Nigeria Enugu Campus, Nigeria). This cooperation supports scientific exchange with a high‑burden region and reflects the Academy’s commitment to global knowledge transfer and capacity building.
A recent highlight that exemplifies this mission was an online lecture on 23 September 2025 titled “Epidemiology of Hepatitis D in Mongolia, and Screening Among Mongol Migrants in Stockholm”. The session was delivered by Dr. Naranjargal Dashdorj (The Liver Center & Onom Foundation, Ulaanbaatar, Mongolia) and Dr. Habiba Kamal (Unit for Clinical Infectious Diseases, Karolinska Institutet, Sweden; D‑SOLVE member). It provided insights into Mongolia’s high HDV burden and presented screening approaches among Mongolian migrants in Stockholm, illustrating how global perspectives enrich the consortium’s knowledge base and inform clinical pathways.
Through this combination of training, mobility, and international cooperation, the D‑SOLVE Academy amplifies the D‑SOLVE spirit: rigorous science, open exchange, and shared standards for better patient outcomes. Its activities ensure that new insights reach practice—building lasting expertise for the HDV community in Europe and beyond.
February 25, 2026
D SOLVE Academy: Empowering Exchange, Elevating Hepatitis D Care
The D‑SOLVE Academy is the training and exchange hub of the D‑SOLVE project. It connects clinicians, researchers, and early‑career scientists across Europe with the shared goal of accelerating progress in diagnostics, monitoring, and care for hepatitis D (HDV). By coordinating structured exchanges between D‑SOLVE partners, delivering targeted education, and building international links, the Academy ensures that scientific advances translate efficiently into clinical practice. The Academy is also open for scientists and physicians from other institutes and clinical hospitals (“train the trainer”), extending its impact beyond the consortium.
At its core, the Academy enables practical, hands‑on learning through bilateral site visits and short‑term exchanges among D‑SOLVE partner institutions. These visits foster direct knowledge transfer in HDV diagnostics and patient management, help align clinical workflows and methodologies, and strengthen collaboration between clinical and research teams.
Training is anchored by the D‑SOLVE Translational Seminar Series, which bridges basic science and clinical practice in viral hepatitis – with a focus on HBV/HDV – through curated sessions for experts and young investigators; a detailed summary is available in a separate news post on this website.
Beyond Europe, the Academy has also initiated targeted international collaboration, including an emerging partnership with Nigerian researcher Dr. Ijeoma Ifeorah (Department of Medical Laboratory Sciences, College of Medicine, University of Nigeria Enugu Campus, Nigeria). This cooperation supports scientific exchange with a high‑burden region and reflects the Academy’s commitment to global knowledge transfer and capacity building.
A recent highlight that exemplifies this mission was an online lecture on 23 September 2025 titled “Epidemiology of Hepatitis D in Mongolia, and Screening Among Mongol Migrants in Stockholm”. The session was delivered by Dr. Naranjargal Dashdorj (The Liver Center & Onom Foundation, Ulaanbaatar, Mongolia) and Dr. Habiba Kamal (Unit for Clinical Infectious Diseases, Karolinska Institutet, Sweden; D‑SOLVE member). It provided insights into Mongolia’s high HDV burden and presented screening approaches among Mongolian migrants in Stockholm, illustrating how global perspectives enrich the consortium’s knowledge base and inform clinical pathways.
Through this combination of training, mobility, and international cooperation, the D‑SOLVE Academy amplifies the D‑SOLVE spirit: rigorous science, open exchange, and shared standards for better patient outcomes. Its activities ensure that new insights reach practice—building lasting expertise for the HDV community in Europe and beyond.
February 25, 2026
D SOLVE Academy: Empowering Exchange, Elevating Hepatitis D Care
The D‑SOLVE Academy is the training and exchange hub of the D‑SOLVE project. It connects clinicians, researchers, and early‑career scientists across Europe with the shared goal of accelerating progress in diagnostics, monitoring, and care for hepatitis D (HDV). By coordinating structured exchanges between D‑SOLVE partners, delivering targeted education, and building international links, the Academy ensures that scientific advances translate efficiently into clinical practice. The Academy is also open for scientists and physicians from other institutes and clinical hospitals (“train the trainer”), extending its impact beyond the consortium.
At its core, the Academy enables practical, hands‑on learning through bilateral site visits and short‑term exchanges among D‑SOLVE partner institutions. These visits foster direct knowledge transfer in HDV diagnostics and patient management, help align clinical workflows and methodologies, and strengthen collaboration between clinical and research teams.
Training is anchored by the D‑SOLVE Translational Seminar Series, which bridges basic science and clinical practice in viral hepatitis – with a focus on HBV/HDV – through curated sessions for experts and young investigators; a detailed summary is available in a separate news post on this website.
Beyond Europe, the Academy has also initiated targeted international collaboration, including an emerging partnership with Nigerian researcher Dr. Ijeoma Ifeorah (Department of Medical Laboratory Sciences, College of Medicine, University of Nigeria Enugu Campus, Nigeria). This cooperation supports scientific exchange with a high‑burden region and reflects the Academy’s commitment to global knowledge transfer and capacity building.
A recent highlight that exemplifies this mission was an online lecture on 23 September 2025 titled “Epidemiology of Hepatitis D in Mongolia, and Screening Among Mongol Migrants in Stockholm”. The session was delivered by Dr. Naranjargal Dashdorj (The Liver Center & Onom Foundation, Ulaanbaatar, Mongolia) and Dr. Habiba Kamal (Unit for Clinical Infectious Diseases, Karolinska Institutet, Sweden; D‑SOLVE member). It provided insights into Mongolia’s high HDV burden and presented screening approaches among Mongolian migrants in Stockholm, illustrating how global perspectives enrich the consortium’s knowledge base and inform clinical pathways.
Through this combination of training, mobility, and international cooperation, the D‑SOLVE Academy amplifies the D‑SOLVE spirit: rigorous science, open exchange, and shared standards for better patient outcomes. Its activities ensure that new insights reach practice—building lasting expertise for the HDV community in Europe and beyond.












